|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ahmad R, Alam M, Hasegawa M, Uchida Y,
Al-Obaid O, Kharbanda S and Kufe D: Targeting MUC1-C inhibits the
AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal
cancer. Mol Cancer. 16:332017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kasprzak A, Siodła E, Andrzejewska M,
Szmeja J, Seraszek-Jaros A, Cofta S and Szaflarski W: Differential
expression of mucin 1 and mucin 2 in colorectal cancer. World J
Gastroenterol. 24:4164–4177. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Singh R and Bandyopadhyay D: MUC1: A
target molecule for cancer therapy. Cancer Biol Ther. 6:481–486.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Taylor-Papadimitriou J, Burchell J, Miles
DW and Dalziel M: MUC1 and cancer. Biochim Biophys Acta.
1455:301–313. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nath S and Mukherjee P: MUC1: A
multifaceted oncoprotein with a key role in cancer progression.
Trends Mol Med. 20:332–342. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guo M, You C and Dou J: Role of
transmembrane glycoprotein mucin 1 (MUC1) in various types of
colorectal cancer and therapies: Current research status and
updates. Biomed Pharmacother. 107:1318–1325. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Smith JS, Colon J, Madero-Visbal R, Isley
B, Konduri SD and Baker CH: Blockade of MUC1 expression by glycerol
guaiacolate inhibits proliferation of human breast cancer cells.
Anticancer Agents Med Chem. 10:644–6650. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Apostolopoulos V, Pietersz GA and McKenzie
IF: MUC1 and breast cancer. Curr Opin Mol Ther. 1:98–103.
1999.PubMed/NCBI
|
|
10
|
Yang E, Hu XF and Xing PX: Advances of
MUC1 as a target for breast cancer immunotherapy. Histol
Histopathol. 22:905–922. 2007.PubMed/NCBI
|
|
11
|
Agrawal B, Krantz MJ, Reddish MA and
Longenecker BM: Cancer-associated MUC1 mucin inhibits human T-cell
proliferation, which is reversible by IL-2. Nat Med. 4:43–49. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van de Wiel-van Kemenade E, Ligtenberg MJ,
de Boer AJ, Buijs F, Vos HL, Melief CJ, Hilkens J and Figdor CG:
Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell
interaction. J Immunol. 151:767–776. 1993.PubMed/NCBI
|
|
13
|
Topalian SL, Drake CG and Pardoll DM:
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor
immunity. Curr Opin Immunol. 24:207–212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tang J, Yu JX, Hubbard-Lucey VM,
Neftelinov ST, Hodge JP and Lin Y: Trial watch: The clinical trial
landscape for PD1/PDL1 immune checkpoint inhibitors. Nat Rev Drug
Discov. 17:854–855. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ma YF, Chen C, Li D, Liu M, Lv ZW, Ji Y
and Xu J: Targeting of interleukin (IL)-17A inhibits PDL1
expression in tumor cells and induces anticancer immunity in an
estrogen receptor-negative murine model of breast cancer.
Oncotarget. 5:7614–7624. 2017. View Article : Google Scholar
|
|
16
|
Baldus SE, Engelmann K and Hanisch FG:
MUC1 and the MUCs: A family of human mucins with impact in cancer
biology. Crit Rev Clin Lab Sci. 41:189–231. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goldman MJ, Craft B, Hastie M, Repečka K,
McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, et al:
Visualizing and interpreting cancer genomics data via the Xena
platform. Nat Biotechnol. 38:675–678. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cancer Genome Atlas Network: Comprehensive
molecular characterization of human colon and rectal cancer.
Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Helfinger V, Henke N, Harenkamp S, Walter
M, Epah J, Penski C, Mittelbronn M and Schröder K: The NADPH
oxidase Nox4 mediates tumour angiogenesis. Acta Physiol (Oxf).
216:435–446. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Koboziev I, Karlsson F and Grisham MB:
Gut-associated lymphoid tissue, T cell trafficking, and chronic
intestinal inflammation. Ann N Y Acad Sci. 1207 (Suppl 1):E86–E93.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Terzić J, Grivennikov S, Karin E and Karin
M: Inflammation and colon cancer. Gastroenterology.
138:2101–2114.e5. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gajewski TF, Schreiber H and Fu YX: Innate
and adaptive immune cells in the tumor microenvironment. Nat
Immunol. 14:1014–1022. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Villarreal DO, L'Huillier A, Armington S,
Mottershead C, Filippova EV, Coder BD, Petit RG and Princiotta MF:
Targeting CCR8 induces protective antitumor immunity and enhances
vaccine-induced responses in colon cancer. Cancer Res.
78:5340–5348. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Amarnath S, Mangus CW, Wang JC, Wei F, He
A, Kapoor V, Foley JE, Massey PR, Felizardo TC, Riley JL, et al:
The PDL1-PD1 axis converts human TH1 cells into regulatory T cells.
Sci Transl Med. 3:111ra1202011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Beatty P, Ranganathan S and Finn OJ:
Prevention of colitis-associated colon cancer using a vaccine to
target abnormal expression of the MUC1 tumor antigen.
Oncoimmunology. 1:263–270. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dmitrieva-Posocco O, Dzutsev A, Posocco
DF, Hou V, Yuan W, Thovarai V, Mufazalov IA, Gunzer M, Shilovskiy
IP, Khaitov MR, et al: Cell-type-specific responses to
interleukin-1 control microbial invasion and tumor-elicited
inflammation in colorectal cancer. Immunity. 50:166–180.e7. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang K and Karin M: Tumor-elicited
inflammation and colorectal cancer. Adv Cancer Res. 128:173–196.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen J, Pitmon E and Wang K: Microbiome,
inflammation and colorectal cancer. Semin Immunol. 32:43–53. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Farhood B, Najafi M and Mortezaee K:
CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A
review. J Cell Physiol. 234:8509–8521. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bianchi G, Borgonovo G, Pistoia V and
Raffaghello L: Immunosuppressive cells and tumour microenvironment:
Focus on mesenchymal stem cells and myeloid derived suppressor
cells. Histol Histopathol. 26:941–951. 2011.PubMed/NCBI
|
|
32
|
Liu Y and Cao X: Immunosuppressive cells
in tumor immune escape and metastasis. J Mol Med (Berl).
94:509–522. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Muenst S, Schaerli AR, Gao F, Däster S,
Trella E, Droeser RA, Muraro MG, Zajac P, Zanetti R, Gillanders WE,
et al: Expression of programmed death ligand 1 (PD-L1) is
associated with poor prognosis in human breast cancer. Breast
Cancer Res Treat. 146:15–24. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sabatier R, Finetti P, Mamessier E,
Adelaide J, Chaffanet M, Ali HR, Viens P, Caldas C, Birnbaum D and
Bertucci F: Prognostic and predictive value of PDL1 expression in
breast cancer. Oncotarget. 6:5449–5464. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Maeda T, Hiraki M, Jin C, Rajabi H, Tagde
A, Alam M, Bouillez A, Hu X, Suzuki Y, Miyo M, et al: MUC1-C
induces PD-L1 and immune evasion in triple-negative breast cancer.
Cancer Res. 78:205–215. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Curiel TJ, Wei S, Dong H, Alvarez X, Cheng
P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, et
al: Blockade of B7-H1 improves myeloid dendritic cell-mediated
antitumor immunity. Nat Med. 9:562–567. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ghebeh H, Tulbah A, Mohammed S, Elkum N,
Bin Amer SM, Al-Tweigeri T and Dermime S: Expression of B7-H1 in
breast cancer patients is strongly associated with high
proliferative Ki-67-expressing tumor cells. Int J Cancer.
121:751–758. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu Y, Zeng B, Zhang Z, Zhang Y and Yang
R: B7-H1 on myeloid-derived suppressor cells in immune suppression
by a mouse model of ovarian cancer. Clin Immunol. 129:471–481.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Parsa AT, Waldron JS, Panner A, Crane CA,
Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, et
al: Loss of tumor suppressor PTEN function increases B7-H1
expression and immunoresistance in glioma. Nat Med. 13:84–88. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xiao W, Ibrahim ML, Redd PS, Klement JD,
Lu C, Yang D, Savage NM and Liu K: Loss of Fas expression and
function is coupled with colon cancer resistance to immune
checkpoint inhibitor immunotherapy. Mol Cancer Res. 17:420–430.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Noy R and Pollard JW: Tumor-associated
macrophages: From mechanisms to therapy. Immunity. 41:49–61. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wherry EJ: T cell exhaustion. Nat Immunol.
12:492–499. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lucas J, Hsieh TC, Halicka HD,
Darzynkiewicz Z and Wu JM: Upregulation of PD-L1 expression by
resveratrol and piceatannol in breast and colorectal cancer cells
occurs via HDAC3/p300-mediated NF-κB signaling. Int J Oncol.
53:1469–1480. 2018.PubMed/NCBI
|
|
45
|
Stenehjem DD, Tran D, Nkrumah MA and Gupta
S: PD1/PDL1 inhibitors for the treatment of advanced urothelial
bladder cancer. Onco Targets Ther. 11:5973–5989. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zheng A, Li F, Chen F, Zuo J, Wang L, Wang
Y, Chen S, Xiao B and Tao Z: PD-L1 promotes head and neck squamous
cell carcinoma cell growth through mTOR signaling. Oncol Rep.
41:2833–2843. 2019.PubMed/NCBI
|
